ArticleFrontiers in immunology2025
Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting survival of Hodgkin lymphoma using machine learning-an analysis based on the SEER database.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Combination antiretroviral therapy (cART)-mediated immune reconstitution can establish a tumor-permissive microenvironment. In addition, compromised immune surveillance may contribute to more aggressive disease phenotypes in HIV patients; however, clinical evidence remains limited. Methods: We conducted a retrospective analysis of clinical data of newly diagnosed Hodgkin lymphoma (HL) patients from 2014 to 2024 treated at four medical centers in China. The authors conducted clinical and immune function analysis of HIV-positive HL patients with special emphasis on prognosis and immune factors. Results: In total, 19 patients were diagnosed as HIV positive. HIV-positive HL patients (HIV-HL) had more advanced stage disease, ECOG-PS, bulky disease, and B symptoms compared to HL patients without HIV (n=130). HIV-positive HL patients had decreased CD4 cell count, CD4/CD8, and GZMB. Lower CD4 count was associated with more bulky disease and B symptoms and higher IL-2R and IL-6 levels in HIV-HL patients. And HIV-HL patients with bulky disease had less GZMB compared to non-bulky disease patients. The enrichment impact of gene alterations on bulky disease demonstrated that PI3K/AKT, thyroid hormone signaling, NF-kappa B signaling pathway, and EBV infection were involved. Immune dysfunction (CD4, CD8, and CD4/CD8), on the other hand, showed no association with survival in both HIV-positive and negative HL patients. There were similar outcomes in patients with and without HIV treated by ABVD chemotherapy. Conclusion: HIV-associated Hodgkin lymphoma (HIV-HL) often presents with more aggressive clinical features, although outcomes are similar to those observed in HIV-negative HL patients. Impaired immune function may contribute to an increased tumor burden through multiple mechanisms. However, it was not associated with outcomes. HL treatment approaches might not necessarily require adjustment solely due to HIV status, but additional clinical evidence is needed to support this assertion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.